Condition: Adult Congenital Heart Disease · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
This is a mono-center observational ambispective study in which adult patients with congenital heart disease evaluated at our institution will be enrolled. The primary endopoint is to assess the clinical and echocardiographic predictors of adverse events during follow-up (death, arrhythmias, cardiac hospitalization). The secondary endpoints are: 1) evaluation of the incidence of the singular components of the primary endpoint; 2) evaluation of the prognostic impact of acquired lesions, including valve disease not present at birth; 3) need for surgical/percutaneous interventions during follow up. Participants will be evaluated in the context of scheduled follow-up visits in our Outpatient ACHD Clinic. No interventions/drug administration will be performed other than those required by standard clinical practice.
This description comes directly from the study's public registry record.
Francesca Graziani, MD, PhD · 00390630154432 · francesca.graziani@policlinicogemelli.it
Giulia Iannaccone, MD · 00390630154432 · giulia.iannaccone@guest.policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario Agostino Gemelli | Rome, RM, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06723704